Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

New Antidiabetic Therapies: A Paradigm Shift in Type 2 Diabetes Management

Author(s): Theocharis Koufakis, Niki Katsiki and Kalliopi Kotsa

Volume 27, Issue 8, 2021

Published on: 08 March, 2021

Page: [1007 - 1007] Pages: 1

DOI: 10.2174/138161282708210308141311

Next »
[1]
Felekos I, Karamasis GV, Pavlidis AN. PCSK9 inhibitors for the management of dyslipidemia in people with Type 2 Diabetes: How low is too low? Curr Pharm Des 2021; 27: 1008-14.
[http://dx.doi.org/10.2174/1381612826666200617170252]
[2]
Sharma S, Bhatia V. Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods. Curr Pharm Des 2021; 27: 1015-24.
[http://dx.doi.org/10.2174/1381612826666201118094502]
[3]
Kyriakidou A, Koufakis T, Goulis DG, Vasilopoulos Y, Zebekakis P, Kotsa K. Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. Curr Pharm Des 2021; 27: 1025-34.
[http://dx.doi.org/10.2174/1381612826666201203145654]
[4]
Papazafiropoulou AK, Melidonis A, Antonopoulos S. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes. Curr Pharm Des 2021; 27: 1035-42.
[http://dx.doi.org/10.2174/1381612826666200909142126]
[5]
Georgianos PI, Vaios V, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Mechanisms of cardiorenal protection with SGLT-2 inhibitors. Curr Pharm Des 2021; 27: 1043-50.
[http://dx.doi.org/10.2174/1381612827666210119102409]
[6]
Karangelis D, Mazer CD, Stakos D, et al. Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: focus on heart failure. Curr Pharm Des 2021; 27: 1051-60.
[http://dx.doi.org/10.2174/1381612826666201103122813]
[7]
Grammatiki M, Sagar R, Ajjan R. Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm? Curr Pharm Des 2021; 27: 1061-7.
[http://dx.doi.org/10.2174/1381612826666201222154616]
[8]
Zafeiropoulos S, Pagiantza A, Doundoulakis I, et al. Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap. Curr Pharm Des 2021; 27: 1068-79.
[http://dx.doi.org/10.2174/1381612827666210119103153]
[9]
Vas PRJ, Vainieri E, Patel N. Pharmacological treatments for diabetic foot disease: current state and future perspectives. Curr Pharm Des 2021; 27: 1080-92.
[http://dx.doi.org/10.2174/1381612826666201207102423]

Rights & Permissions Print Cite
Article Metrics
6
1
© 2024 Bentham Science Publishers | Privacy Policy